2025-05-28 08:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board |
2025-05-08 08:05 | UU:RNAZ | | News Release200 | TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported |
2025-05-05 17:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split |
2025-05-02 16:10 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces 1-for-28 Reverse Stock Split |
2025-05-01 09:01 | UU:RNAZ | | News Release200 | TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer |
2025-04-21 16:30 | UU:RNAZ | | News Release200 | TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting |
2025-03-27 16:37 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 |
2025-03-25 18:24 | UU:RNAZ | | News Release200 | TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering |
2025-03-23 23:11 | UU:RNAZ | | News Release200 | TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules |
2025-03-13 07:47 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial |
2025-02-25 16:15 | UU:RNAZ | | News Release200 | TransCode Therapeutics, Inc. Announces Results of Special Meeting |
2025-02-06 08:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial |
2025-02-04 16:15 | UU:RNAZ | | News Release200 | TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting |
2025-01-14 08:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial |
2025-01-07 08:00 | UU:RNAZ | | News Release200 | Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements |
2024-12-18 08:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial |
2024-11-29 16:25 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split |
2024-11-27 07:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics, Inc. Announces $8 Million Private Placement |
2024-11-25 07:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces 1-for-33 Reverse Stock Split |
2024-11-12 07:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Open Letter to Shareholders |
2024-11-05 07:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance |
2024-10-23 07:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data |
2024-10-10 07:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology |
2024-09-17 07:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate |
2024-09-10 07:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate's Preclinical Efficacy Against Metastatic Cancer |
2024-09-05 07:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate |
2024-08-15 07:00 | UU:RNAZ | | News Release200 | TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation |
2024-07-24 16:05 | UU:RNAZ | | News Release200 | TransCode Therapeutics, Inc. Announces Closing of Public Offering |
2024-07-22 22:30 | UU:RNAZ | | News Release200 | TransCode Therapeutics, Inc. Announces Pricing of Public Offering |
2024-07-22 16:07 | UU:RNAZ | | News Release200 | TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock |